BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

Twitter

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Expert Insights into Recent Updates for the Management of Lower-Risk MDS

New Horizons in the Management of Lower-Risk MDS

Videos

Guillermo Garcia-Manero, MD, discusses recent advances presented at ASH 2023 in the treatment of myelodysplastic syndrome, highlighting both safety and efficacy of regimens in the frontline and second line setting.

Dr Garica-Manero provides a brief overview of the current treatment paradigm for lower-risk MDS as well as discussing some unmet needs. 

Lower-Risk MDS: Current Treatment Landscape and Unmet Needs

Guillermo Garcia-Manero, MD, highlights data updates presented at ASH 2023, outlining current and emerging therapies in frontline and second line lower-risk myelodysplastic syndrome (MDS).

Approved and Emerging Regimens for Frontline and Second Line Lower-Risk MDS

Dr. Garcia-Manero provides an overview of the toxicity profiles for therapies and mitigation strategies for patients with lower-risk MDS.

Toxicity Management for Therapies in Lower-Risk MDS

Future perspective on the growing treatment landscape for patients with MDS.

New Horizons in the Management of MDS

New Horizons in the Management of MDS

EP: 1.Lower-Risk MDS: Current Treatment Landscape and Unmet Needs

EP: 2.Approved and Emerging Regimens for Frontline and Second Line Lower-Risk MDS

EP: 3.Toxicity Management for Therapies in Lower-Risk MDS

EP: 4.New Horizons in the Management of MDS